Skip to Main Content

Paper Details

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Am J Hematol
11
2021
FLT3, FLT3 gatekeeper, gatekeeper mutation, gilteritinib
Aniline Compounds, Cell Line, Tumor, Drug Resistance, Neoplasm, Humans, Leukemia, Myeloid, Acute, Models, Molecular, Mutation, Protein Kinase Inhibitors, Pyrazines, fms-Like Tyrosine Kinase 3
Author NameAffiliation
Sunil K JoshiOregon Health & Science University
Sunil K JoshiOregon Health & Science University
Sunil K JoshiKnight Cancer Institute, Oregon Health & Science University
Setareh SharzehiKnight Cancer Institute, Oregon Health & Science University
Setareh SharzehiOregon Health & Science University
Setareh SharzehiOregon Health & Science University
Janet PittsenbargerKnight Cancer Institute, Oregon Health & Science University
Janet PittsenbargerOregon Health & Science University
Daniel BottomlyKnight Cancer Institute, Oregon Health & Science University
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University
Cristina E TognonOregon Health & Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerOregon Health & Science University
Brian J DrukerOregon Health & Science University
Elie TraerKnight Cancer Institute, Oregon Health & Science University
Elie TraerOregon Health & Science University
Elie TraerOregon Health & Science University
  • 1 - 20

Datasets

Release 1.2